A bill to require the Attorney General to make a determination as to whether cannabidiol should be a controlled substance and listed in a schedule under the Controlled Substances Act and to expand research on the potential medical benefits of cannabidiol and other marijuana components.
Cannabidiol Research Expansion Act
This bill requires the Drug Enforcement Administration (DEA) and the Department of Health and Human Services to each evaluate whether cannabidiol, the nonpsychoactive substance derived from marijuana or the synthetic formulation, should be a controlled substance under the Controlled Substances Act. After taking into consideration the evaluations, the DEA must initiate proceedings for classifying cannabidiol as a controlled substance if control is warranted.
The bill expands the authority for: (1) conducting medical research on cannabidiol, and (2) possessing or transporting cannabidiol or any other nonpsychoactive component of marijuana for certain medicinal purposes.
Physicians who are licensed under state law may discuss the potential harms and benefits of cannabidiol or those components of marijuana as a treatment with their patients or the legal guardians of underage patients.
The bill terminates four years after enactment.
Introduced in Senate
Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S5169)
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line